GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gabather AB (OSTO:GABA) » Definitions » EV-to-FCF

Gabather AB (OSTO:GABA) EV-to-FCF : -2.37 (As of Apr. 09, 2025)


View and export this data going back to 2014. Start your Free Trial

What is Gabather AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Gabather AB's Enterprise Value is kr8.00 Mil. Gabather AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was kr-3.38 Mil. Therefore, Gabather AB's EV-to-FCF for today is -2.37.

The historical rank and industry rank for Gabather AB's EV-to-FCF or its related term are showing as below:

OSTO:GABA' s EV-to-FCF Range Over the Past 10 Years
Min: -33.21   Med: 0.64   Max: 2.66
Current: -2.15

During the past 11 years, the highest EV-to-FCF of Gabather AB was 2.66. The lowest was -33.21. And the median was 0.64.

OSTO:GABA's EV-to-FCF is ranked worse than
100% of 548 companies
in the Drug Manufacturers industry
Industry Median: 24.07 vs OSTO:GABA: -2.15

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-09), Gabather AB's stock price is kr0.0376. Gabather AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.101. Therefore, Gabather AB's PE Ratio (TTM) for today is At Loss.


Gabather AB EV-to-FCF Historical Data

The historical data trend for Gabather AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gabather AB EV-to-FCF Chart

Gabather AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.09 -2.85 -5.78 -1.68 -2.59

Gabather AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.68 -3.25 -3.13 -1.96 -2.59

Competitive Comparison of Gabather AB's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Gabather AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gabather AB's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gabather AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Gabather AB's EV-to-FCF falls into.


;
;

Gabather AB EV-to-FCF Calculation

Gabather AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8.003/-3.375
=-2.37

Gabather AB's current Enterprise Value is kr8.00 Mil.
Gabather AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gabather AB  (OSTO:GABA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Gabather AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0376/-0.101
=At Loss

Gabather AB's share price for today is kr0.0376.
Gabather AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.101.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Gabather AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Gabather AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Gabather AB Business Description

Traded in Other Exchanges
N/A
Address
Forskargatan 20J, Byggn 215 N, Sodertalje, SWE, 151 36
Gabather AB is engaged in developing novel drugs to treat several diseases originating in the central nervous system. It has four main focus areas anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as cognition-enhancing treatments, including for Alzheimer's disease.

Gabather AB Headlines

No Headlines